Anti-OPGL [9H7]

Absolute Antibody

Anti-OPGL [9H7]

9

This antibody is specific for human OPGL. In vivo experiments have shown cross reactivity with Cynomolgus Monkey OPGL.

The binding affinity of this antibodys original format (human IgG1) to hOPGL was confirmed by ELISA. Its binding kinetics to hOPGL 140 and hOPGL 158 was measured by SPR analysis; a KD of 0.193 nM was measured for hOPGL 140. This antibody was evaluated for its neutralizing activity against osteoclast formation induced by Osteoprotegerin ligand (OPGL) using RAW 264.7 cells, as measured by tartrate-resistant acid phosphatase (TRAP) activity; it inhibited osteoclast formation in a dose-dependent manner with an IC50 of 129 ng/ml. This antibodys pharmacokinetics and in vivo activity were assessed in cynomolgus monkeys. The antibodys levels in the serum declined slowly over the testing period; the last detectable measurement on day 49 showed a serum concentration of ~100 ng/ml. serum N-telopeptide (serum N-Tx) levels were greatly reduced compared to baseline immediately following injection (~minus 45%), further decreased to ~minus 75% over four days, and remained stable for a period of two weeks, after which they began to gradually increase until no longer lower than baseline in a statistically significant manner between day 35 to 42 (US7718776B2).

ELISA, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

9H7

TNFSF11

TNF superfamily member 11

CD254; hRANKL2; ODF; OPGL; OPTB2; osteoclast differentiation factor; osteoprotegerin ligand; RANKL; receptor activator of nuclear factor kappa B ligand; sOdf; TNF-related activation-induced cytokine; TNLG6B; TRANCE; tumor necrosis factor (ligand) superfamily, member 11; tumor necrosis factor ligand 6B; tumor necrosis factor ligand superfamily member 11; tumor necrosis factor superfamily member 11

Human

IgG1

Tumor necrosis factor ligand superfamily member 11

Human, Monkey

-20°C,2°C to 8°C

12352203